Aromatase inhibitors in post-menopausal metastatic breast carcinoma
Paolo Carlini(National Cancer Institute), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), E. Terzoli(Catholic University of America), Emilio Bria(Università Cattolica del Sacro Cuore), Giulio Metro(University of Perugia), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Fabiana Letizia Cecere, Francesco Cognetti(Apple (Israel)), Carmen Nuzzo, Maria Simona Pino(Massachusetts General Hospital), Federica Cuppone(Italian Medicines Agency), Alain Gelibter(Policlinico Umberto I), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Michèle Milella(National Cancer Institute)
Cited by 5
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932